Research Article

Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, 210009, China

‡Authors contributed equally

Search for more papers by this author

Xinnian Yu‡

https://orcid.org/0000-0001-9441-8587

Department of Internal Medicine, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, 210009, China

‡Authors contributed equally

Search for more papers by this author

Andi Xu‡

https://orcid.org/0000-0002-9804-0996

Department of Pathology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210008, China

‡Authors contributed equally

Search for more papers by this author

Huixin Li

https://orcid.org/0000-0001-6976-8323

Department of Gynecology, Women's Hospital of Nanjing Medical University, Nanjing Maternity & Child Health Care Hospital, Nanjing, 210004, China

Search for more papers by this author

Wei Chen

https://orcid.org/0000-0002-5593-2396

Department of Head & Neck Surgery, The Affiliated Cancer Hospital of Nanjing, Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, 210009, China

Search for more papers by this author

Shanliang Zhong

*Author for correspondence: Tel.: +86 25 8328 3335;

E-mail Address: slzhong@njmu.edu.cn

https://orcid.org/0000-0001-8200-0511

Center of Clinical Laboratory Science, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, 210009, China

Search for more papers by this author

Published Online:21 Feb 2023https://doi.org/10.2217/epi-2022-0349

View article

Abstract

Aim: To explore the roles of transfer RNA-derived small RNAs (tsRNAs) in endometrial carcinoma (EC). Materials & methods: tsRNA profiles for EC from TCGA were analyzed. The functions and mechanisms of tsRNA were explored using in vitro experiments. Results: 173 dysregulated tsRNAs were identified. After validating in EC tissues and serumal exosome samples from EC patients, a downregulated tsRNA in both EC tissues and serumal exosomes (i.e., tRF-20-S998LO9D) was observed. Exosomal tRF-20-S998LO9D had an area under the curve of 0.768. tRF-20-S998LO9D overexpression inhibited proliferation, migration and invasion and promoted apoptosis of EC cells and tRF-20-S998LO9D knockdown further confirmed its effects. Further analyses showed that tRF-20-S998LO9D upregulated SESN2 in protein levels. Conclusion: tRF-20-S998LO9D inhibits EC cells by upregulating SESN2.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

Reference

1. Raglan O, Kalliala I, Markozannes G et al. Risk factors for endometrial cancer: an umbrella review of the literature. Int. J. Cancer 145(7), 1719–1730 (2019).
Medline CASGoogle Scholar
2. Lu KH, Broaddus RR. Endometrial cancer. N. Engl. J. Med. 383(21), 2053–2064 (2020).
Medline CASGoogle Scholar
3. Njoku K, Abiola J, Russell J, Crosbie EJ. Endometrial cancer prevention in high-risk women. Best Pract. Res. Clin. Obstet. Gynaecol. 65, 66–78 (2020).
MedlineGoogle Scholar
4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
MedlineGoogle Scholar
5. Sundar S, Balega J, Crosbie E et al. BGCS uterine cancer guidelines: recommendations for practice. Eur. J. Obstet. Gynecol. Reprod. Biol. 213, 71–97 (2017).
MedlineGoogle Scholar
6. Colombo N, Creutzberg C, Amant F et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann. Oncol. 27(1), 16–41 (2016).
Medline CASGoogle Scholar
7. Concin N, Matias-Guiu X, Vergote I et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int. J. Gynecol. Cancer 31(1), 12–39 (2021). •• Introduced guidelines for the management of patients with endometrial carcinoma.
MedlineGoogle Scholar
8. Raffone A, Travaglino A, Raimondo D et al. Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma. Gynecol. Oncol. 162(2), 401–406 (2021).
MedlineGoogle Scholar
9. Talhouk A, Mcconechy MK, Leung S et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer 123(5), 802–813 (2017).
Medline CASGoogle Scholar
10. Mcalpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J. Pathol. 244(5), 538–549 (2018).
MedlineGoogle Scholar
11. Zhang L, Yu D. Exosomes in cancer development, metastasis, and immunity. Biochim. Biophys. Acta Rev. Cancer 1871(2), 455–468 (2019).
Medline CASGoogle Scholar
12. Mashouri L, Yousefi H, Aref AR, Ahadi AM, Molaei F, Alahari SK. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol. Cancer 18(1), 75 (2019). • Summarized findings about exosomes.
MedlineGoogle Scholar
13. Wang J, Zhang Q, Wang D et al. Microenvironment-induced TIMP2 loss by cancer-secreted exosomal miR-4443 promotes liver metastasis of breast cancer. J. Cell. Physiol. 235(7–8), 5722–5735 (2020).
Medline CASGoogle Scholar
14. Wang J, Zhang Q, Zhou S et al. Circular RNA expression in exosomes derived from breast cancer cells and patients. Epigenomics 11(4), 411–421 (2019).
CASGoogle Scholar
15. Zhong S, Chen X, Wang D et al. MicroRNA expression profiles of drug-resistance breast cancer cells and their exosomes. Oncotarget 7(15), 19601–19609 (2016).
MedlineGoogle Scholar
16. Zhu L, Li J, Gong Y et al. Exosomal tRNA-derived small RNA as a promising biomarker for cancer diagnosis. Mol. Cancer 18(1), 74 (2019). •• Explored transfer RNA-derived small RNAs (tsRNAs) in exosomes.
MedlineGoogle Scholar
17. Wang J, Ma G, Ge H et al. Circulating tRNA-derived small RNAs (tsRNAs) signature for the diagnosis and prognosis of breast cancer. NPJ Breast Cancer 7(1), 4 (2021).
Medline CASGoogle Scholar
18. Jin F, Yang L, Wang W et al. A novel class of tsRNA signatures as biomarkers for diagnosis and prognosis of pancreatic cancer. Mol. Cancer 20(1), 95 (2021).
Medline CASGoogle Scholar
19. Wang T, Cao L, He S et al. Small RNA sequencing reveals a novel tsRNA-06018 playing an important role during adipogenic differentiation of hMSCs. J. Cell Mol. Med. 24(21), 12736–12749 (2020).
Medline CASGoogle Scholar
20. Li J, Zhu L, Cheng J, Peng Y. Transfer RNA-derived small RNA: a rising star in oncology. Semin. Cancer Biol. doi: 10.1016/j.semcancer.2021.05.024 (2021). •• Summarized the current understanding of the roles of tsRNAs in cancer
Google Scholar
21. Fang S, He T, Jiang J, Li Y, Chen P. Osteogenic effect of tsRNA-10277-loaded exosome derived from bone mesenchymal stem cells on steroid-induced osteonecrosis of the femoral head. Drug Des. Devel. Ther. 14, 4579–4591 (2020).
Medline CASGoogle Scholar
22. Jia Y, Tan W, Zhou Y. Transfer RNA-derived small RNAs: potential applications as novel biomarkers for disease diagnosis and prognosis. Ann. Transl. Med. 8(17), 1092 (2020).
Medline CASGoogle Scholar
23. Pliatsika V, Loher P, Telonis AG, Rigoutsos I. MINTbase: a framework for the interactive exploration of mitochondrial and nuclear tRNA fragments. Bioinformatics 32(16), 2481–2489 (2016).
Medline CASGoogle Scholar
24. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15(12), 550 (2014).
MedlineGoogle Scholar
25. Zhong S, Lin Z, Chen H, Mao L, Feng J, Zhou S. The m(6)A-related gene signature for predicting the prognosis of breast cancer. PeerJ 9, e11561 (2021).
MedlineGoogle Scholar
26. Xie Y, Yao L, Yu X, Ruan Y, Li Z, Guo J. Action mechanisms and research methods of tRNA-derived small RNAs. Signal Transduct. Target Ther. 5(1), 109 (2020).
Medline CASGoogle Scholar
27. Kumar P, Anaya J, Mudunuri SB, Dutta A. Meta-analysis of tRNA derived RNA fragments reveals that they are evolutionarily conserved and associate with AGO proteins to recognize specific RNA targets. BMC Biol. 12, 78 (2014).
MedlineGoogle Scholar
28. Kuscu C, Kumar P, Kiran M, Su Z, Malik A, Dutta A. tRNA fragments (tRFs) guide ago to regulate gene expression post-transcriptionally in a Dicer-independent manner. RNA 24(8), 1093–1105 (2018).
Medline CASGoogle Scholar
29. Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 48(D1), D127–D131 (2020).
Medline CASGoogle Scholar
30. Enright AJ, John B, Gaul U, Tuschl T, Sander C, Marks DS. MicroRNA targets in Drosophila. Genome Biol. 5(1), R1 (2003).
MedlineGoogle Scholar
31. Kruger J, Rehmsmeier M. RNAhybrid: microRNA target prediction easy, fast and flexible. Nucleic Acids Res. 34, W451–454 (2006).
Medline CASGoogle Scholar
32. Shannon P, Markiel A, Ozier O et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13(11), 2498–2504 (2003).
Medline CASGoogle Scholar
33. Zhou SY, Chen W, Yang SJ et al. Circular RNA circVAPA regulates breast cancer cell migration and invasion via sponging miR-130a-5p. Epigenomics 12(4), 303–317 (2020).
CASGoogle Scholar
34. Li K, Lin Y, Luo Y et al. A signature of saliva-derived exosomal small RNAs as predicting biomarker for esophageal carcinoma: a multicenter prospective study. Mol. Cancer 21(1), 21 (2022). •• Explored saliva-derived exosomal small RNAs.
Medline CASGoogle Scholar
35. Poller W, Dimmeler S, Heymans S et al. Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. Eur. Heart J. 39(29), 2704–2716 (2018).
Medline CASGoogle Scholar
36. He C, Zheng S, Luo Y, Wang B. Exosome theranostics: biology and translational medicine. Theranostics 8(1), 237–255 (2018).
Medline CASGoogle Scholar
37. Wang C, Li Z, Liu Y, Yuan L. Exosomes in atherosclerosis: performers, bystanders, biomarkers, and therapeutic targets. Theranostics 11(8), 3996–4010 (2021).
Medline CASGoogle Scholar
38. Shen Y, Yu X, Zhu L, Li T, Yan Z, Guo J. Transfer RNA-derived fragments and tRNA halves: biogenesis, biological functions and their roles in diseases. J. Mol. Med. 96(11), 1167–1176 (2018). • Summarized biogenesis and biological functions of tsRNAs.
MedlineGoogle Scholar
39. Goodarzi H, Liu X, Nguyen H, Zhang S, Fish L, Tavazoie S. Endogenous tRNA-derived fragments suppress breast cancer progression via YBX1 displacement. Cell 161(4), 790–802 (2015).
Medline CASGoogle Scholar
40. Wen JT, Huang ZH, Li QH, Chen X, Qin HL, Zhao Y. Research progress on the tsRNA classification, function, and application in gynecological malignant tumors. Cell Death Discov. 7(1), 388 (2021).
Medline CASGoogle Scholar
41. Cordani M, Sánchez-Álvarez M, Strippoli R, Bazhin A, Donadelli M. Sestrins at the interface of ROS control and autophagy regulation in health and disease. Oxid. Med. Cellul. Longev. 2019, 1283075 (2019).
MedlineGoogle Scholar
42. Wang BJ, Wang S, Xiao M et al. Regulatory mechanisms of Sesn2 and its role in multi-organ diseases. Pharmacol. Res. 164, 105331 (2021).
Medline CASGoogle Scholar
43. Kim H, Yin K, Falcon DM, Xue X. The interaction of hemin and sestrin2 modulates oxidative stress and colon tumor growth. Toxicol. Appl. Pharmacol. 374, 77–85 (2019).
Medline CASGoogle Scholar
44. Pham DV, Raut PK, Pandit M et al. Globular adiponectin inhibits breast cancer cell growth through modulation of inflammasome activation: critical role of sestrin2 and AMPK signaling. Cancers (Basel) 12(3), 613 (2020).
Medline CASGoogle Scholar
45. Wei JL, Fang M, Fu ZX et al. Sestrin 2 suppresses cells proliferation through AMPK/mTORC1 pathway activation in colorectal cancer. Oncotarget 8(30), 49318–49328 (2017).
MedlineGoogle Scholar
46. Hua X, Xu J, Deng X et al. New compound ChlA-F induces autophagy-dependent anti-cancer effect via upregulating sestrin-2 in human bladder cancer. Cancer Lett. 436, 38–51 (2018).
Medline CASGoogle Scholar
47. Jeong S, Kim DY, Kang SH et al. Docosahexaenoic acid enhances oxaliplatin-induced autophagic cell death via the ER stress/Sesn2 pathway in colorectal cancer. Cancers (Basel) 11(7), 982 (2019).
Medline CASGoogle Scholar
48. Shin J, Bae J, Park S et al. mTOR-dependent role of sestrin2 in regulating tumor progression of human endometrial cancer. Cancers (Basel) 12(9), 2515 (2020).
Medline CASGoogle Scholar
49. Troisi J, Mollo A, Lombardi M et al. The metabolomic approach for the screening of endometrial cancer: validation from a large cohort of women scheduled for gynecological surgery. Biomolecules 12(9), 1229 (2022).
Medline CASGoogle Scholar
50. Raffone A, Troisi J, Boccia D et al. Metabolomics in endometrial cancer diagnosis: a systematic review. Acta Obstet. Gynecol. Scand. 99(9), 1135–1146 (2020). •• Summarized metabolomics in endometrial cancer diagnosis.
MedlineGoogle Scholar
51. Xu H, Gong Z, Shen Y, Fang Y, Zhong S. Circular RNA expression in extracellular vesicles isolated from serum of patients with endometrial cancer. Epigenomics 10(2), 187–197 (2018). • Explored circular RNAs in extracellular vesicles.
CASGoogle Scholar
52. Zhou L, Wang W, Wang F et al. Plasma-derived exosomal miR-15a-5p as a promising diagnostic biomarker for early detection of endometrial carcinoma. Mol. Cancer 20(1), 57 (2021).
Medline CASGoogle Scholar

Vol. 14, No. 24

Supplemental Materials

Metrics

Downloaded 150 times

History

Received 6 October 2022

Accepted 8 February 2023

Published online 21 February 2023

Published in print December 2022

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/epi-2022-0349

Author contributions

S Zhong conceived and designed the experiments; T Qian, X Yu, A Xu and H Li performed the experiments; T Qian and W Chen analyzed the data; S Zhong and T Qian drafted the work or revised it critically for important content.

Financial & competing interests disclosure

This study was funded by the Science and Technology Development Fund project of Jiangsu Cancer Hospital (grant number ZJ202125), the National Natural Science Foundation of China (grant number 81902725) and the Young Talents Program of Jiangsu Cancer Hospital (grant number QL201810). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethics statement

The studies involving human participants were reviewed and approved by the Ethics Committee of Nanjing Medical University. The patients/participants provided their written informed consent to participate in this study.

PDF download

tRF-20-S998LO9D inhibits endometrial carcinoma by upregulating SESN2

Abstract

Reference